东曜药业-B(01875)前三季度营业收入6.22亿元

Core Insights - Dongyao Pharmaceutical-B (01875) reported a revenue of RMB 622 million for the nine-month period ending September 30, 2025, indicating the company's financial performance during this timeframe [1] - The company recorded a net loss attributable to equity holders of RMB 3.371 million during the same period, highlighting ongoing financial challenges [1] Financial Performance - Revenue for the nine-month period was RMB 622 million, reflecting the company's operational scale [1] - The net loss for the period was RMB 3.371 million, which indicates a negative financial outcome for equity holders [1]